Cargando…

Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart

Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control. However, the precise mechanism(s) by which GLP-1 treatment renders cardioprotection during myocardial ischemia remain unresolved. Here we examined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aravindhan, Karpagam, Bao, Weike, Harpel, Mark R., Willette, Robert N., Lepore, John J., Jucker, Beat M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476748/ https://www.ncbi.nlm.nih.gov/pubmed/26098939 http://dx.doi.org/10.1371/journal.pone.0130894

Ejemplares similares

Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency
por: Bao, Weike, et al.
Publicado: (2011)

Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury
por: Bao, Weike, et al.
Publicado: (2013)

Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
por: Bao, Weike, et al.
Publicado: (2013)

Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
por: Basalay, Marina V., et al.
Publicado: (2016)

Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia
por: Giblett, Joel P., et al.
Publicado: (2016)

Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1
por: Clarke, Sophie J, et al.
Publicado: (2014)

Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death
por: Kadowaki, Sachiko, et al.
Publicado: (2023)

Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies
por: Giblett, Joel P., et al.
Publicado: (2016)

High FGF23 Levels Failed to Predict Cardiac Hypertrophy in Animal Models of Hyperphosphatemia and Chronic Renal Failure
por: Moench, Ian, et al.
Publicado: (2021)

Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
por: McLean, Brent A., et al.
Publicado: (2022)

Glucagon changes substrate preference in gluconeogenesis
por: Xu, Huiting, et al.
Publicado: (2022)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection()()
por: Ussher, John R., et al.
Publicado: (2014)

Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion
por: Giblett, Joel P., et al.
Publicado: (2019)

High Glucose Attenuates Cardioprotective Effects of Glucagon-Like Peptide-1 Through Induction of Mitochondria Dysfunction via Inhibition of β-Arrestin-Signaling
por: Pan, Xietian, et al.
Publicado: (2021)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Abscisic Acid Stimulates Glucagon-Like Peptide-1 Secretion from L-Cells and Its Oral Administration Increases Plasma Glucagon-Like Peptide-1 Levels in Rats
por: Bruzzone, Santina, et al.
Publicado: (2015)

Acute administration of interleukin‐6 does not increase secretion of glucagon‐like peptide‐1 in mice
por: Christiansen, Charlotte B., et al.
Publicado: (2018)

Intraperitoneal administration of nesfatin-1 stimulates glucagon-like peptide-1 secretion in fasted mice
por: Tagawa, Noriko, et al.
Publicado: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Silencing RNA for MMPs May Be Utilized for Cardioprotection
por: Banaszkiewicz, Marta, et al.
Publicado: (2022)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs
por: Volpe, Sara, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Mechanisms involved in adenosine pharmacological preconditioning-induced cardioprotection
por: Singh, Lovedeep, et al.
Publicado: (2018)

Cardioprotective Properties of Mannitol—Involvement of Mitochondrial Potassium Channels
por: Feige, Katharina, et al.
Publicado: (2021)

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
por: Yan, Yilong, et al.
Publicado: (2023)

Cardioprotective effects of co-administration of thymoquinone and ischemic postconditioning in diabetic rats
por: Ran, Junchuan, et al.
Publicado: (2021)

Utilizing Red Spotted Apollo Butterfly Transcriptome to Identify Antimicrobial Peptide Candidates against Porphyromonas gingivalis
por: Lee, Kang-Woon, et al.
Publicado: (2021)

Direct cardiovascular effects of glucagon like peptide-1
por: Sheikh, Asfandyar
Publicado: (2013)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Glucagon‐related peptides and the regulation of food intake in chickens
por: Honda, Kazuhisa
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1rrrf0s06stos2vk9e8j3024hp